A Phase I Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FR945;-Targeting Bispecific T cell Engager, in Subjects with Relapsed/Refractory Ovarian Carcinoma

Study Identifier:
NTB928.01
CT.gov Identifier:
N/A
EudraCT Identifier:
N/A
EU Trial (CTIS) Number:
N/A
Study Contact Information:
N/A
Will Be Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

To assess NTB-928, a FR945;-Targeting Bispecific T cell Engager, in Subjects with Relapsed/Refractory Ovarian Carcinoma

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Ovarian
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
I
Sex
N/A
Age
N/A
Study Drug
Drug: Patients will receive NTB-928
Study Status
Indicates the current recruitment status or the expanded access status
Will Be Recruiting

Requirements information
Inclusion criteria
  • Inclusion Criteria:
  • Patients with relapsed/refractory Ovarian Carcinoma

Clinical Study Information for Healthcare Providers

By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

View Study Information

Study Locations

Location
Investigator
Status
Condition(s) Treated at Site
Location
START New York (Long Island)
Lake Success, NY, United States, 11042
Investigator
Geraldine O'Sullivan Coyne
Status
Will Be Recruiting
Condition(s) Treated at Site
Ovarian
Location
START Dallas Fort Worth
Fort Worth, TX, United States, 76104
Investigator
Henry Xiong
Status
Will Be Recruiting
Condition(s) Treated at Site
Ovarian